Edwards EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Decision date Feb 1, 2024
What did the FDA approve?
The FDA approved the Edwards EVOQUE Tricuspid Valve Replacement System on February 1, 2024, under PMA number P230013. The applicant is Edwards Lifesciences, LLC, and the device is classified under product code NPW as a percutaneously delivered prosthesis and tricuspid valve in the cardiovascular specialty.
The approval statement describes the device as indicated for improving health status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, when a heart team deems tricuspid valve replacement appropriate. This is a reported intended use, not independent proof of safety or clinical effectiveness. The record does not include supplement type, supplement reason, or additional clinical data.
FDA approval order statement
Approval for the Edwards EVOQUE Tricuspid Valve Replacement System. The device is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy (OMT), in whom tricuspid valve replacement is deemed appropriate by a heart team.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 1, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230013
- Regulatory pathway
- Premarket approval application
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- Decision code
- APPR
- Decision date
- Feb 1, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230013 received
Application receipt date recorded by FDA.
P230013 · FDA decision
APPR
P230013/S027 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S029 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S033 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S034 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)
Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EVOQUE Tricuspid Valve Replacement SystemP230013/S027 | Edwards Lifesciences, LLC | PMA supplement | Sep 16, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 19, 2026 | FDA | |
EVOQUE Tricuspid Valve Replacement SystemP230013/S033 | Edwards Lifesciences, LLC | PMA supplement | Oct 21, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P230013
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records